How has the COVID-19 pandemic impacted prescribing pancreatic enzyme replacement to people with unresectable pancreatic cancer? medrxivpreprint UniOfSurrey UniofOxford unibirmingham COVID19 coronavirus covid enzyme cancer pancreas pandemic
By Neha MathurJul 13 2022Reviewed by Danielle Ellis, B.Sc. In a recent study posted to the medRxiv* preprint server, researchers evaluated the impact of the coronavirus disease 2019 pandemic on the rates of pancreatic enzyme replacement therapy prescribing in England.
About the study In the present study, researchers used the OpenSAFELY-TPP platform to conduct an automated audit of 24 million adults with unresectable pancreatic cancer receiving PERT between 1 January 2015 and 31 March 2022. The study dataset covered over 40% of England’s population and was pseudonymized, which means all primary care patient records included coded diagnoses, medications, and physiological parameters. OpenSAFELY-TPP offered several technical and organizational controls.
Study findings The authors observed an insubstantial dip of around 3% in PERT prescribing to people with unresectable pancreatic cancer between March and July 2020, i.e., at the beginning of the COVID-19 pandemic. However, the rates again surged to normal levels by September 2020.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
How can we define early COVID-19 reinfections?How can we define early COVID-19 reinfections? CDCgov SARSCoV2 COVID19 Coronavirus Reinfection
Lire la suite »
Pregnant women at increased risk of COVID-19 severityPregnant women at increased risk of COVID-19 severity UofT SARSCoV2 COVID19 COVIDSeverity Pregnancy
Lire la suite »
COVID-19 restrictions could be reintroduced if rise in cases hits NHS backlog, minister warnsHealth minister Lord Kamall says if the increase in coronavirus cases affects the NHS backlog 'then clearly measures may well have to be introduced'.
Lire la suite »
Patients with lupus benefit from COVID-19 vaccine boosterPeople with systemic lupus erythematosus (SLE) who received a 'booster' dose of SARS-CoV-2 vaccine after full vaccination are roughly half as likely to have a subsequent 'breakthrough' COVID-19 infection, a new study shows.
Lire la suite »